Navigation Links
Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011
Date:5/16/2011

INDIANAPOLIS, May 16, 2011 /PRNewswire/ -- Data on nine Lilly Oncology molecules in development will be presented during the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Ill. from June 3 – 7, 2011.  Lilly Oncology's pipeline is one of the largest in the industry, with more than 30 molecules in development to treat various types of cancer.  

Nearly all of these pipeline molecules are being evaluated for certain biomarkers or genetic mutations that can help researchers identify which patients are most likely to respond to these medicines, and as importantly, which are not.  

At ASCO, Lilly will present Phase II data on two fully human IgG1 monoclonal antibodies: cixutumumab for the treatment of patients with advanced or metastatic soft tissue sarcoma and Ewing family of tumors; and ramucirumab for the treatment of locally advanced or metastatic breast cancer.  Lilly will also present data on a Phase I study of LY2127399, a human anti-BAFF antibody for patients with previously-treated multiple myeloma.  Additionally, Lilly will present data from several studies of enzastaurin, a selective serine-threonine kinase inhibitor that targets the PKC Beta and PI3/AKT pathways.

"Lilly is very much in alignment with this year's ASCO conference theme, 'Patients, Pathways, Progress,'" said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology.  "Our extensive oncology pipeline targets important pathways and specific genetic mutations that can lead to cancer, which we hope will enable us to come up with better therapies, more quickly.  This is part of our commitment to changing the world of cancer care," he added.    

Select studies, as well as the times and locations of the data sessions, are highlighted below.

Cixutumumab (IMC-A12)

  • Abstract # 10004: Oral Abstract Session: Monday, June 6, 2011, 4:15 PM - 4:30 PM
    • Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft tissue sarcoma and Ewing family of tumors.
    • Author/Speaker: P. Schoffski, D. Adkins, J. Y. Blay, T. Gil, A. D. Elias, P. Rutkowski, G. K. Pennock, H. Youssoufian, N. J. Zojwalla, R. Willey, D. O. Grebennik
    • Location: E354a

Ramucirumab (IMC-1121B)

  • Abstract #TPS151: Trials in Progress Poster Session: Monday, June 6, 2011, 8:00 AM - 12:00 PM
    • Randomized phase 2 study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402).
    • Author/Speaker: L. T. Vahdat, K. Miller, J. A. Sparano, H. Youssoufian, J. D. Schwartz, S. Nanda, W. Wang, L. Abad, A. Dontabhaktuni, M. D. Rutstein
    • Location: Hall A; Poster Board 42E

Anti-BAFF antibody (LY2127399)

  • Abstract #8012: Oral Abstract Session: Sunday, June 5, 2011, 11:15 AM - 11:30 AM
    • Phase 1 study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously-treated multiple myeloma
    • Author/Speaker: Noopur Raje, Raymond Hohl, Edward Faber, Paul Richardson, Andres Forero, Gary Schiller, Adam Cohen, Susan Carpenter, Damien Cronier, Maksim Pashkevich, James Wooldridge, Kenneth Anderson
    • Location: E354a

Enzastaurin

  • Abstract # 8016: Poster Discussion Session: Saturday, June 4, 2011, 8:00 AM - 12:00 PM
    • Randomized Phase II Study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate and high-risk diffuse large B-cell lymphoma (DLBCL) – Preliminary Analysis
    • Author/Speaker: John D. Hainsworth, Edward R. Arrowsmith, Michael McCleod, Luis E. Fayad, Oday Hamid, Lori Davis, Boris Lin
    • Location: E450b; Poster Board: 2
  • Abstract # 1507: Oral Abstract Session: Monday, June 6, 2011, 5:15 PM - 5:30 PM
    • Final Results of a Chemoprevention Trial with Enzastaurin in Former Smokers
    • Author/Speaker: J. Gray, S. Altiok, M. Alexandrow, F. Walsh, J. Chen, D. Tai, G. Bepler
    • Location: S100bc

TGF-beta molecule (LY2157299)

  • Abstract # 3011: Poster Discussion Session: Saturday, June 4, 2011, 2:00 PM - 6:00 PM
    • First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma.
    • Author/Speaker: Jordi Rodon Ahnert
    • Location: S403; Poster Board #1

P-LLY

This press release contains forward-looking statements about the potential of cixutumumab, ramucirumab, enzastaurin, LY2127399 and LY2157299 and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the products will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery ... Okaloosa County Emergency Medical Services (EMS) ... and one LT2 van. Quality Emergency Vehicles in ... for the sale.  This is the latest in Demers, ongoing ... Vice President at Demers. --> Benoit LaFortune , ...
(Date:2/12/2016)... ALISO VIEJO , Kalifornien, 12. Februar 2016 ... es mit der Aufnahme von Patienten für eine ... Embolisation von Aneurysmen („WEB") speziell für die Behandlung ... Laurent Spelle , MD, Leiter der Neuroradiologie an ... , Frankreich, und Hauptprüfarzt der CLARYS-Studie hat den ...
(Date:2/12/2016)... and SEOUL, South Korea , ... and Macrogen, Inc. today announced they will form ... procedures for precision medicine in cancer. The goal ... DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next Generation ... under the Clinical Laboratory Improvement Amendments (CLIA) of ...
Breaking Medicine Technology:
(Date:2/13/2016)... City, Utah (PRWEB) , ... February 13, 2016 , ... When an Au Pair ... Parents aren’t always sure what they are in for and they are often worried things ... more than they were hoping for. This year’s Au Pair of the Year winner’s all ...
(Date:2/12/2016)... San Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... of love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. ... in fact a love story, the love of a Buddhist teacher for teaching and ...
(Date:2/12/2016)... ... ... Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – 12:30 ... don’t learn from history are doomed to repeat it.” , An analysis of CDRH’s enforcement ... that takes time. , Take a close look at the warning letters the agency ...
(Date:2/12/2016)... ... ... Coco Libre, the maker of coconut water beverages with a purpose, is ... Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, a ... suite, held this year at the W Hollywood Hotel, has become a pre-show “must” ...
(Date:2/12/2016)... ... , ... Every winter, someone is killed, injured or loses a home in ... part of the Allegheny Health Network, has partnered with Etna Volunteer Fire Department, ... Space” campaign. , “Space Heaters Need Space” aims to bring awareness to ...
Breaking Medicine News(10 mins):